Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RARA | P10276 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11111164 | 0.98 | RARB (0.58) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL938923 | 0.94 | RARB (0.61) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL11440914 | 0.92 | RARB (0.62) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL10583573 | 0.92 | RARB (0.62) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL589884 | 0.87 | ALDH1A1 (0.56) | RARBALDH1A1MEN1RARAMAPT | |
| Terephthalic Acid SCHEMBL8743595 | 0.87 | ALDH1A1 (0.56) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL371605 | 0.87 | RARB (0.71) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL133470 | 0.87 | RARB (0.68) | RARBALDH1A1MEN1RARAMAPT | |
| Paraben SCHEMBL5310602 | 0.86 | DPP4 (0.59) | MAOAESR1CYP19A1ESR2HTR2A | |
| Hydrochloric Acid SCHEMBL872073 | 0.85 | KMT2A (0.56) | RARBALDH1A1MEN1RARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415553-A | The thermosetting resin of plasticising and related solidified resin, curing method and the product comprising solidified resin | 马萨诸塞大学 | 2019-03-01 | — | — | CN | claimed |
| US-20250059083-A1 | GLASS CONTAINER COATED INTERNALLY WITH A METAL-ORGANIC FRAMEWORK | UNIVERSIDAD DE LA LAGUNA (ES) | 2025-02-20 | — | — | US | disclosed |
| EP-4454753-A1 | GLASS CONTAINER COATED INTERNALLY WITH A METAL-ORGANIC FRAMEWORK | Universidad de la Laguna, OTRI (ES) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023163986-A1 | SILOXANE DERIVATIVES OF AMINO ACIDS HAVING SURFACE-ACTIVE PROPERTIES | ADVANSIX RESINS & CHEMICALS LLC (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023118628-A1 | GLASS CONTAINER COATED INTERNALLY WITH A METAL-ORGANIC FRAMEWORK | UNIVERSIDAD DE LA LAGUNA (ES) | 2023-06-29 | — | — | WO | disclosed |
| CN-111205291-B | Triazolo ring compound, preparation method, intermediate and application thereof | 上海科技大学 | 2022-08-23 | — | — | CN | disclosed |
| US-10796910-B2 | Method for performing a photolithography process | TAIWAN SEMICONDUTOR MANUFACTURING CO., LTD. (TW) | 2020-10-06 | — | — | US | disclosed |
| US-10738041-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2020-08-11 | — | — | US | disclosed |
| CN-111205291-A | Triazolo ring compound, preparation method, intermediate and application thereof | 上海科技大学 | 2020-05-29 | — | — | CN | disclosed |
| US-20200135452-A1 | METHOD FOR PERFORMING A PHOTOLITHOGRAPHY PROCESS | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2020-04-30 | — | — | US | disclosed |
| US-9708413-B2 | Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof | GLYTECH, INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150299337-A1 | GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF | GLYTECH INC (JP) | 2015-10-22 | — | — | US | disclosed |
| US-6716978-B2 | FOR THERAPY AND PROHYLAXIS OF INFLAMMATORY DISEASES INCLUDING JOINT INFLAMMATION, CROHN'S DISEASE, AND INFLAMMATORY BOWEL DISEASE; RESPIRATORY DISEASES SUCH AS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING ASTHMA, CHRONIC BRONCHITIS | PFIZER INC | 2004-04-06 | — | — | US | disclosed |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | MARFAT ANTHONY (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0254009-B1 | A PROCESS FOR PURIFYING DINITROANILINE HERBICIDES | AGAN CHEMICAL MANUFACTURERS LTD. (IL) | 1991-04-17 | — | — | EP | disclosed |
| US-4970343-A | CONTACTING IN LIQUID STATE WITH HYDROBROMIDE SALT OF AMINO-BENZOIC ACID ESTER, DEHYDRATING | AGAN CHEMICAL MANUFACTURERS LTD. (IL) | 1990-11-13 | — | — | US | disclosed |
| EP-0254009-A1 | A process for purifying dinitroaniline herbicides | AGAN CHEMICAL MANUFACTURERS LTD. (IL) | 1988-01-27 | — | — | EP | disclosed |
| US-4537992-A | ACYLHALIDES AND AMINOBENZOATE ESTERS | AGAN CHEMICAL MANUFACTURERS, LTD. (IL) | 1985-08-27 | — | — | US | disclosed |
| US-4536391-A | REACTING A PLASMIN HEAVY CHAIN WITH UROKINASE IN THE PRESENCE OF A COUPLING AGENT | OTSUKA PHARMACEUTICAL CO. (JP) | 1985-08-20 | — | — | US | disclosed |
| EP-0109653-A2 | Process for preparing urokinase complex | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299337-A1 | GLYCOSYLATED LINKER, COMPOUND CONTAINING GLYCOSYLATED LINKER MOIETY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE MOIETY OR SALT THEREOF, AND METHODS FOR PRODUCING SAID U OR SALT THEREOF | CD44, CSGALNACT1, UGGT1 | RARB 3090/4885ALDH1A1 594/4885MEN1 1350/4885 |
| US-10738041-B2 | Ferroportin inhibitors | SLC40A1, HAMP, TFRC | RARB 2270/4885ALDH1A1 1968/4885MEN1 1655/4885 |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | PDE3B, ALPI, PDE4B | RARB 1595/4885ALDH1A1 2163/4885MEN1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.